BALAXI PHARMACEUTICALS LIMITED — Interim / Quarterly Report 2025

Jun 7, 2025

MOHITH KUMAR Digitally signed by MOHITH KUMAR KHANDELWAL KHANDELWAL Date: 2025.06.07 11:38:23 +05'30'

==> picture [173 x 34] intentionally omitted <==

==> picture [740 x 34] intentionally omitted <==

==> picture [94 x 27] intentionally omitted <==

==> picture [208 x 18] intentionally omitted <==

==> picture [716 x 95] intentionally omitted <==

==> picture [735 x 325] intentionally omitted <==

==> picture [522 x 273] intentionally omitted <==

==> picture [222 x 24] intentionally omitted <==

==> picture [72 x 15] intentionally omitted <==

==> picture [142 x 120] intentionally omitted <==

==> picture [719 x 442] intentionally omitted <==

Particulars(InRcrore)	Q4FY24
Revenue	59.83
	30.95
GrossMargin%	51.7%
EBITDA	11.68
EBITDAMargin%	19.5%
ProfitAfterTax	10.93
PATMargin%	18.3%
EarningPerShare(INR)	2.08

==> picture [174 x 376] intentionally omitted <==

==> picture [200 x 353] intentionally omitted <==

==> picture [62 x 13] intentionally omitted <==

==> picture [61 x 63] intentionally omitted <==

==> picture [58 x 316] intentionally omitted <==